Table 3 Clinico-pathological characteristics of patients with MIBC treated with definite CCRT.
From: The role of PD-L1 in the radiation response and clinical outcome for bladder cancer
| Â | No. of patients | p value | |
|---|---|---|---|
PD-L1 (−) | PD-L1 (+) | ||
Age | Â | Â | 0.64 |
 Median | 71.8 | 73.3 |  |
 Range | 48.5–90.2 | 46.5–88.2 |  |
Gender | Â | Â | 0.61 |
 Male | 22 (73%) | 32 (76%) |  |
 Female | 8 (27%) | 10 (24%) |  |
Pathologic grade | Â | Â | 0.16 |
 Low-intermediate | 15 (50%) | 28 (67%) |  |
 High | 15 (50%) | 14 (33%) |  |
Clinical stage | Â | Â | 0.005* |
 T2 | 21 (70%) | 18 (43%) |  |
 T3-T4 | 9 (30%) | 24 (57%) |  |
Clinical LN involvement | Â | Â | 0.066 |
 Negative | 24 (80%) | 25 (60%) |  |
 Positive | 6 (20%) | 17 (40%) |  |
RT dose (cGy) | Â | Â | 0.29 |
 mean | 5819 | 5820 |  |
 median | 6000 | 5940 |  |
Response to | |||
definite CCRT | |||
 CR (+) | 27 (90%) | 24 (57%) | 0.002* |
 CR (−) | 3 (10%) | 18 (43%) |  |
Distant metastasis | Â | Â | 0.55 |
 Negative | 24 (80%) | 32 (76%) |  |
 Positive | 6 (20%) | 10 (24%) |  |
Loco-regional failure | |||
 Negative | 23 (77%) | 15 (36%) | 0.000* |
 Positive | 7 (23%) | 27 (64%) |  |
Survival rate | |||
 5yr OS | 75% | 55% | 0.113 |
 5yr DFS | 60% | 32% | 0.029* |
 5yr DSS | 88% | 65% | 0.032* |
 5yr survival with bladder | 74% | 46% | 0.011* |
